Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ and ZetaMAST™ for Treatment of Metastatic Bone and Soft Tissue Lesions

Press Published by 3rd Party PR Representative on:  
nvestor Inquiries:

Zetagen Therapeutics, Inc.
Email: InvestorRelations@zetagen.com

Media Inquiries:

McDougall Communications on Behalf of Zetagen Therapeutics, Inc.
Laura DiCaprio, Senior Counselor, laura@mcdougallpr.com Phone: +1-585-773-8005